PAR

3.77%

25.5¢ paradigm biopharmaceuticals limited..

those who blindly follow will not believe anythiing you say, but...

First 57 Last

Share
Profile

Follow
FatChoy

77 Posts.

30

29/02/24

11:01

Post #: 72665367
Share

Originally posted by Robbie1: ↑

Mozz,

Always liked reading your posts and appreciate the time you have put in to researching the science.

The comment below though I disagree with.

"I now know a deal signed back then is NOT ANYTHING like a future deal to be signed....especially the OA Global...they need to hold out on that one for longer definitely....they need to auction that..."

By holding out on a deal (if this is what happened) PAR has had to do a raise and by the looks of it, another raise soon. Basic math's means that a deal with a 20% royalty today equates to a 15% royalty deal 1 year ago. This is due to dilution. All this bulls @ # t regarding squeezing a few extra percentage points of a royalty is all pointless if we need to raise again. It's also putting the long term survival of the business and getting Zilusol to market at risk.

At the time, if there was genuine interest, PR should have accepted a royalty as low as 12% prior to the 2 most recent raises.

A possible scenario (pure speculation by me at the moment) is Paul scared all the pharma companies off being overly aggressive on a deal and not factoring in the reality that by doing a deal earlier but for less than he wanted would have actually be better for shareholders than doing a deal for more after dilution has occurred.

The whole thing seems to be management naivety which was left unchecked due to poor governance and a lack of contrarian views on the board.

Expand

those who blindly follow will not believe anythiing you say, but well done for trying.

PAR Price at posting: 34.0¢ Sentiment: Sell Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

OPL

Opyl forms JV with UK and US consortium to bring products to the world

AAI

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

HXL

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

There are more pages in this discussion • 3 more messages in this thread...

First 57 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change -0.010(3.77%)		Mkt cap ! $89.19M

Open	High	Low	Value	Volume
27.0¢	27.0¢	25.5¢	$162.7K	620.9K

Buyers (Bids)

No.	Vol.	Price($)
2	25008	25.5¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	34768	1

View Market Depth

No.	Vol.	Price($)
2	25008	0.255
8	215150	0.250
7	117763	0.245
8	101034	0.240
2	54200	0.235

Price($)	Vol.	No.
0.260	34768	1
0.270	500	1
0.275	6347	2
0.290	24580	4
0.295	10000	2

Last trade - 16.10pm 26/07/2024 (20 minute delay)

PAR (ASX) Chart

those who blindly follow will not believe anythiing you say, but...

Opyl forms JV with UK and US consortium to bring products to the world

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Geochemical work at Newington picks up gold and copper anomalies for Midas

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

those who blindly follow will not believe anythiing you say, but...

Top Stories

Opyl forms JV with UK and US consortium to bring products to the world

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Geochemical work at Newington picks up gold and copper anomalies for Midas

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News